Erratum to 'Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients': [ESMO Open Volume 7, Issue 1, February 2022, 100393].
作者信息
Beechinor R, Palumbo A, Chew H K, Arora M
机构信息
UC Davis Comprehensive Cancer Center, Sacramento; University of California, San Francisco School of Pharmacy, San Francisco.
Department of Pharmacy, Oregon Health and Science University, Portland.
出版信息
ESMO Open. 2022 Apr;7(2):100460. doi: 10.1016/j.esmoop.2022.100460. Epub 2022 Mar 17.
Abstract
摘要
相似文献
1
Erratum to 'Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients': [ESMO Open Volume 7, Issue 1, February 2022, 100393].《对“回复：哌柏西利与质子泵抑制剂之间的药物相互作用可能显著影响转移性乳腺癌患者的临床结局”的勘误》：[《ESMO 开放》第 7 卷，第 1 期，2022 年 2 月，100393]
ESMO Open. 2022 Apr;7(2):100460. doi: 10.1016/j.esmoop.2022.100460. Epub 2022 Mar 17.
2
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.帕博西尼与质子泵抑制剂之间的药物相互作用可能会显著影响转移性乳腺癌患者的临床结局。
ESMO Open. 2021 Oct;6(5):100231. doi: 10.1016/j.esmoop.2021.100231. Epub 2021 Sep 9.
3
Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.回复：哌柏西利与质子泵抑制剂之间的药物相互作用可能会显著影响转移性乳腺癌患者的临床结局。
ESMO Open. 2022 Feb;7(1):100393. doi: 10.1016/j.esmoop.2022.100393. Epub 2022 Feb 4.
4
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.对以下评论的回复：哌柏西利与质子泵抑制剂之间的药物相互作用可能会显著影响转移性乳腺癌患者的临床结局。
ESMO Open. 2022 Feb;7(1):100381. doi: 10.1016/j.esmoop.2022.100381. Epub 2022 Feb 4.
5
Letter comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer.关于《哌柏西利与质子泵抑制剂之间的药物相互作用可能显著影响转移性乳腺癌患者的临床结局》的信函评论
ESMO Open. 2022 Feb;7(1):100382. doi: 10.1016/j.esmoop.2022.100382. Epub 2022 Feb 7.
6
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.帕博西尼联合戈舍瑞林与卡培他滨用于激素受体阳性、HER2 阴性转移性乳腺癌绝经前妇女（KCSG-BR15-10）：一项多中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24.
7
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.用于治疗转移性乳腺癌的细胞周期蛋白依赖性激酶抑制剂的最新全面综述。
Curr Med Res Opin. 2017 Sep;33(9):1559-1569. doi: 10.1080/03007995.2017.1348344. Epub 2017 Jul 25.
8
Erratum to 'Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival': [ESMO Open Volume 7, Issue 2, April 2022, 100409].《转移性乳腺癌治疗的重大进展：拓展治疗选择即延长生存期》勘误：[《ESMO 开放》第 7 卷，第 2 期，2022 年 4 月，100409]
ESMO Open. 2022 Jun;7(3):100472. doi: 10.1016/j.esmoop.2022.100472. Epub 2022 Apr 7.
9
Erratum to 'Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome': [ESMO Open Volume 6, Issue 1, February 2021, 100005].《“COVID-19 之前及期间癌症患者血液学和生化参数的纵向特征揭示与预后相关的特征”勘误》：[《ESMO 开放》第 6 卷，第 1 期，2021 年 2 月，100005]
ESMO Open. 2021 Apr;6(2):100056. doi: 10.1016/j.esmoop.2021.100056. Epub 2021 Jan 28.
10
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.比较不同细胞周期蛋白依赖性激酶 4/6 抑制剂在转移性乳腺癌中的治疗相关不良事件：一项网络荟萃分析。
Cancer Treat Rev. 2020 Nov;90:102086. doi: 10.1016/j.ctrv.2020.102086. Epub 2020 Aug 17.
Zotero 插件